Response to Yu et al.

IF 5.1 2区医学 Q1 CELL & TISSUE ENGINEERING Stem Cell Reports Pub Date : 2025-03-11 Epub Date: 2025-02-06 DOI:10.1016/j.stemcr.2025.102400

Yuanyue Liu, Siqi Song, Youyu Liu, Ting Fu, Yanzheng Guo, Ruoqing Liu, Jiexing Chen, Yanchun Lin, Yaqi Cheng, Yun Li, Tian Guan, Shiqi Ling, Haoyu Zeng

引用次数: 0

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

对Yu等人的回应。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Stem Cell Reports CELL & TISSUE ENGINEERING-CELL BIOLOGY

CiteScore

10.50

自引率

1.70%

发文量

200

审稿时长

28 weeks

期刊介绍： Stem Cell Reports publishes high-quality, peer-reviewed research presenting conceptual or practical advances across the breadth of stem cell research and its applications to medicine. Our particular focus on shorter, single-point articles, timely publication, strong editorial decision-making and scientific input by leaders in the field and a "scoop protection" mechanism are reasons to submit your best papers.

期刊最新文献

Exosome-Mediated Benefits of Cell Therapy in Mouse and Human Models of Duchenne Muscular Dystrophy. Cellular immunotherapy for COVID-19-induced acute respiratory distress syndrome: Results of the CIRCA-19 phase 1 safety and phase 2 randomized controlled trials. Nuclear Lipin1 recruits HDAC2 to epigenetically repress SREBP1-dependent lipid synthesis and myelination in hypoxic preterm white matter injury. New legal category of 'advanced regenerative medicine treatment' in Korea's amended regenerative medicine law: comparative lessons from Japan. Comparison with Ezh2 reveals the PRC2-dependent functions of Jarid2 in hematopoietic stem Cell lineage commitment.